|
All cohort studies
|
Only definite nephritis
|
Any SLE patients
|
---|
Outcome
|
Number of cohorts
|
Number of events/patients
|
Percentage with outcome
|
Number of cohorts
|
Number of events/patients
|
Percentage with outcome
|
Number of cohorts
|
Number of events/patients
|
Percentage with outcome
|
---|
Efficacy
| | | | | | | | | |
Complete or partial response
|
7
|
121/151
|
80
|
7
|
121/151
|
80
|
No data
|
Failure/No response
|
8
|
37/176
|
21
|
7
|
30/151
|
20
|
1
|
7/25
|
28
|
Adverse events
| | | | | | | | | |
Adverse event discontinuations
|
9
|
40/285
|
14
|
4
|
6/68
|
8.8
|
5
|
34/217
|
16
|
Lack of efficacy discontinuations
|
5
|
24/235
|
10
|
1
|
4/24
|
17
|
4
|
20/211
|
9.5
|
All infections
|
10
|
76/327
|
23
|
4
|
18/70
|
26
|
6
|
58/257
|
23
|
Serious infections
|
8
|
8/185
|
4.3
|
4
|
4/87
|
4.6
|
4
|
4/98
|
4.1
|
Gastrointestinal (diarrhoea, nausea, vomiting)
|
14
|
122/406
|
30
|
8
|
52/160
|
33
|
6
|
58/257
|
29
|
Leucopaenia
|
8
|
6/188
|
3.2
|
4
|
1/61
|
1.6
|
4
|
5/127
|
3.9
|
Vertigo, dizziness
|
3
|
6/81
|
7.4
|
No data
|
3
|
6/81
|
7.4
|
Hair loss
|
2
|
5/42
|
12
|
1
|
1/13
|
7.7
|
1
|
4/29
|
14
|
- SLE, systemic lupus erythematosus.